IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.296
0.00 (-0.10%)
At close: Feb 21, 2025, 4:00 PM
0.305
+0.009 (3.11%)
After-hours: Feb 21, 2025, 7:57 PM EST
IGC Pharma Revenue
IGC Pharma had revenue of $257.00K in the quarter ending December 31, 2024, with 25.98% growth. This brings the company's revenue in the last twelve months to $1.24M, up 1.64% year-over-year. In the fiscal year ending March 31, 2024, IGC Pharma had annual revenue of $1.35M with 47.64% growth.
Revenue (ttm)
$1.24M
Revenue Growth
+1.64%
P/S Ratio
17.41
Revenue / Employee
$18,448
Employees
67
Market Cap
23.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
| Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
| Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
| Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
| Mar 31, 2020 | 4.07M | -1.04M | -20.41% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
IGC News
- 2 days ago - IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market - Accesswire
- 4 days ago - IGC Pharma Reports Third Quarter Fiscal 2025 Results - Accesswire
- 11 days ago - IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM) - Accesswire
- 25 days ago - IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease - Accesswire
- 5 weeks ago - IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets - Accesswire
- 6 weeks ago - IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy - Accesswire
- 2 months ago - IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 - Accesswire
- 2 months ago - IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology - Accesswire